Chronic Urticaria: An Overview of Treatment and Recent Patents.

CONCLUSION: CU is idiopathic in majority of cases. On average, the duration of CU is around two to five years. Treatment is primarily symptomatic. Second generation antihistamines are first line. Omaluzimab has been a remarkable advance in the management of CU and improves quality of life beyond symptom control. PMID: 30924425 [PubMed - as supplied by publisher]
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research